Yimin Ren
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yimin Ren has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Guangyu Cai
College of Anesthesia, Guizhou Medical University
2 shared publicationsHui Li
Department of Anesthesiology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China
2 shared publicationsYang Liu
Department of Anesthesiology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China
2 shared publicationsZhu Wei
College of Anesthesia, Guizhou Medical University
2 shared publicationsBin Tian
Department of Radiology, The Second People's Hospital of Guiyang, Guizhou Province, Guiyang, 550023, China
1 shared publicationChangmao Jiang
College of Anesthesia, Guizhou Medical University
1 shared publication
Latest Publications
- 10 November 2026
- Published by Springer Nature in Medical Oncology
- Vol. 43 (12) , 384
FGD5-AS1/miR-106b-5p/FDX1 axis governs cuproptosis to affect clear cell renal cell carcinoma progression via metabolic-immune crosstalk
- 10 November 2026
- Published by Springer Nature in Medical Oncology
- Vol. 43 (12) , 384
FGD5-AS1/miR-106b-5p/FDX1 axis governs cuproptosis to affect clear cell renal cell carcinoma progression via metabolic-immune crosstalk
- 22 October 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1782
Targeting NMDAR2A in microglia: esketamine suppresses M1 polarization in BV2 cells
Objective Microglial polarization toward the M1 phenotype is a key contributor to the initiation and progression of neuroinflammatory diseases, primarily through the release of pro-inflammatory cytokines that exacerbate central nervous system-associated injury. Activation of N-methyl-D-aspartic acid receptors (NMDARs) is implicated in microglial overactivation and cytotoxicity. This study aimed to investigate the role of esketamine, a non-competitive NMDAR antagonist, on microglial polarization. Methods BV2 microglial cells were used as an in vitro model. Inhibitors and agonists were applied to modulate the mammalian target of rapamycin (mTOR) and brain-derived neurotrophic factor (BDNF)-tyrosine kinase receptor B (TrkB) signaling pathways. Small interfering RNA, Western blotting, enzyme-linked immunosorbent assay, and immunofluorescence staining were performed to investigate the regulatory effects and molecular targets of esketamine on BV2 cells. Results Esketamine enhanced mTOR phosphorylation and activated the BDNF-TrkB signaling pathway through NMDAR inhibition. This effect attenuated lipopolysaccharide-induced M1 polarization in BV2 microglia and reduced pro-inflammatory cytokine expression. Further analysis revealed that the anti-inflammatory effects of esketamine were primarily mediated by the NMDAR2A subtype, while the NMDAR2B subtype was not involved. Conclusion Esketamine suppressed proinflammatory microglial polarization by selectively modulating the NMDAR2A subtype, leading to the activation of the mTOR signaling pathway and enhancement of the BDNF-TrkB signaling pathway.
- 22 October 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1782
Targeting NMDAR2A in microglia: esketamine suppresses M1 polarization in BV2 cells
Objective Microglial polarization toward the M1 phenotype is a key contributor to the initiation and progression of neuroinflammatory diseases, primarily through the release of pro-inflammatory cytokines that exacerbate central nervous system-associated injury. Activation of N-methyl-D-aspartic acid receptors (NMDARs) is implicated in microglial overactivation and cytotoxicity. This study aimed to investigate the role of esketamine, a non-competitive NMDAR antagonist, on microglial polarization. Methods BV2 microglial cells were used as an in vitro model. Inhibitors and agonists were applied to modulate the mammalian target of rapamycin (mTOR) and brain-derived neurotrophic factor (BDNF)-tyrosine kinase receptor B (TrkB) signaling pathways. Small interfering RNA, Western blotting, enzyme-linked immunosorbent assay, and immunofluorescence staining were performed to investigate the regulatory effects and molecular targets of esketamine on BV2 cells. Results Esketamine enhanced mTOR phosphorylation and activated the BDNF-TrkB signaling pathway through NMDAR inhibition. This effect attenuated lipopolysaccharide-induced M1 polarization in BV2 microglia and reduced pro-inflammatory cytokine expression. Further analysis revealed that the anti-inflammatory effects of esketamine were primarily mediated by the NMDAR2A subtype, while the NMDAR2B subtype was not involved. Conclusion Esketamine suppressed proinflammatory microglial polarization by selectively modulating the NMDAR2A subtype, leading to the activation of the mTOR signaling pathway and enhancement of the BDNF-TrkB signaling pathway.
- Open Access
- 12 August 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
CD63 aptamer–based electrochemical sensor assesses stored red blood cell–derived exosome burden associated with mast-cell–mediated transfusion-related acute lung injury
- 12 August 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessCD63 aptamer–based electrochemical sensor assesses stored red blood cell–derived exosome burden associated with mast-cell–mediated transfusion-related acute lung injury
- Open Access
- 21 May 2026
- Published by Springer Nature in Trials
- Vol. 27 (1)
Cipepofol for adjunctive sedation during neuraxial anesthesia: a study protocol for a randomized controlled trial
Cipepofol is a novel 2,6-disubstituted phenol derivative increasingly used for anesthesia and sedation during gastrointestinal endoscopy and fiberoptic bro
- 21 May 2026
- Published by Springer Nature in Trials
- Vol. 27 (1)
Open AccessCipepofol for adjunctive sedation during neuraxial anesthesia: a study protocol for a randomized controlled trial
Cipepofol is a novel 2,6-disubstituted phenol derivative increasingly used for anesthesia and sedation during gastrointestinal endoscopy and fiberoptic bro
- Open Access
- 24 March 2026
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 20, 1781396
Identifying potential inflammatory therapeutic targets and drug candidates in small fiber neuropathy: integrating Mendelian randomization, experimental validation, and deep learning
Objective: This study aimed to investigate the causal associations between circulating inflammatory proteins and small fiber neuropathy (SFN) by integrating Mendelian randomization (MR) analysis with experimental validation in animal models, and to explore their potential as therapeutic targets. Methods: A two-sample bidirectional MR analysis was conducted to evaluate the genetic causal associations between 91 inflammatory proteins and SFN. A paclitaxel-induced SFN mouse model was developed to assess behavioral changes, intraepidermal nerve fiber density, and the expression levels of key inflammatory factors in serum, dorsal root ganglia, and spinal cord. Computational drug screening using deep learning (TransformerCPI 2.0) combined with molecular docking analysis screened small-molecule candidates with high predicted interaction likelihood to target proteins. Results: MR analysis nominated suggestive associations of C-C motif chemokine ligand 11 (CCL11, odds ratio (OR) = 1.460, 95% confidence interval (CI) = 1.059–2.012, p = 0.021) and interleukin 18 receptor 1 (IL18R1, OR = 1.186, 95% CI = 1.011–1.391, p = 0.036) with increased SFN risk, whereas monocyte chemotactic protein 2 (MCP2) showed a suggestive protective association (OR = 0.842, 95% CI = 0.731–0.970, p = 0.017). However, after Benjamini–Hochberg false discovery rate correction across 91 proteins, none of these associations remained significant. In a murine model, paclitaxel administration induced mechanical hypersensitivity and resulted in a reduction of intraepidermal nerve fiber density. Elevated expression levels of CCL11, MCP2, IL18R1 in affected tissues were observed. Utilizing deep learning and molecular docking techniques, several small-molecule compounds with high binding affinity to these inflammatory targets were screened, indicating their potential as candidate compounds for future therapeutic development. Conclusion: CCL11 and IL18R1 are suggested as potential inflammatory targets in SFN. MCP2 showed discordant genetic and experimental signals, which may reflect context-dependent regulation and differences between genetically predicted long-term effects and acute injury responses. This study applies an integrative framework that integrates genetic prediction, experimental validation, and drug discovery, providing novel insights into SFN pathogenesis and generates hypotheses for future intervention.
- 24 March 2026
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 20, 1781396
Open AccessIdentifying potential inflammatory therapeutic targets and drug candidates in small fiber neuropathy: integrating Mendelian randomization, experimental validation, and deep learning
Objective: This study aimed to investigate the causal associations between circulating inflammatory proteins and small fiber neuropathy (SFN) by integrating Mendelian randomization (MR) analysis with experimental validation in animal models, and to explore their potential as therapeutic targets. Methods: A two-sample bidirectional MR analysis was conducted to evaluate the genetic causal associations between 91 inflammatory proteins and SFN. A paclitaxel-induced SFN mouse model was developed to assess behavioral changes, intraepidermal nerve fiber density, and the expression levels of key inflammatory factors in serum, dorsal root ganglia, and spinal cord. Computational drug screening using deep learning (TransformerCPI 2.0) combined with molecular docking analysis screened small-molecule candidates with high predicted interaction likelihood to target proteins. Results: MR analysis nominated suggestive associations of C-C motif chemokine ligand 11 (CCL11, odds ratio (OR) = 1.460, 95% confidence interval (CI) = 1.059–2.012, p = 0.021) and interleukin 18 receptor 1 (IL18R1, OR = 1.186, 95% CI = 1.011–1.391, p = 0.036) with increased SFN risk, whereas monocyte chemotactic protein 2 (MCP2) showed a suggestive protective association (OR = 0.842, 95% CI = 0.731–0.970, p = 0.017). However, after Benjamini–Hochberg false discovery rate correction across 91 proteins, none of these associations remained significant. In a murine model, paclitaxel administration induced mechanical hypersensitivity and resulted in a reduction of intraepidermal nerve fiber density. Elevated expression levels of CCL11, MCP2, IL18R1 in affected tissues were observed. Utilizing deep learning and molecular docking techniques, several small-molecule compounds with high binding affinity to these inflammatory targets were screened, indicating their potential as candidate compounds for future therapeutic development. Conclusion: CCL11 and IL18R1 are suggested as potential inflammatory targets in SFN. MCP2 showed discordant genetic and experimental signals, which may reflect context-dependent regulation and differences between genetically predicted long-term effects and acute injury responses. This study applies an integrative framework that integrates genetic prediction, experimental validation, and drug discovery, providing novel insights into SFN pathogenesis and generates hypotheses for future intervention.
- 21 September 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 983, 177014
Esketamine improves cognitive function in sepsis-associated encephalopathy by inhibiting microglia-mediated neuroinflammation
- 21 September 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 983, 177014
Esketamine improves cognitive function in sepsis-associated encephalopathy by inhibiting microglia-mediated neuroinflammation